A5030999203- Pulmonary Hypertension Research and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Obstructive Sleep Apnea Research
- Vascular Anomalies and Treatments
- Cardiovascular Issues in Pregnancy
- Neuroscience of respiration and sleep
- Cardiovascular Function and Risk Factors
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Liver Disease and Transplantation
- Cardiovascular and Diving-Related Complications
- Asthma and respiratory diseases
- Heart Failure Treatment and Management
- Congenital Heart Disease Studies
- Venous Thromboembolism Diagnosis and Management
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- High Altitude and Hypoxia
- Medical Imaging and Pathology Studies
- Lung Cancer Diagnosis and Treatment
- Cardiovascular Syncope and Autonomic Disorders
- Lung Cancer Treatments and Mutations
- Emergency and Acute Care Studies
- Sleep and Wakefulness Research
- Cardiovascular and exercise physiology
Centre Hospitalier Régional et Universitaire de Nancy
2016-2025
Université de Lorraine
2016-2025
Inserm
2011-2025
Université de Montpellier
2025
Défaillance Cardiovasculaire Aiguë et Chronique
2018-2024
Délégation Centre-Est
2020-2021
Lille’s Cardiology Hospital
2018
Centre Hospitalier Universitaire de Lille
2018
Respiratory Clinical Trials
2015
Hôpital Antoine-Béclère
2006-2014
Rationale: Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend management in designated centers with multidisciplinary teams working a shared-care approach.Objective: To describe clinical and hemodynamic parameters to provide estimates prevalence of patients diagnosed PAH according standardized definition.Methods: The registry was initiated 17 university hospitals following at least five newly per year. All consecutive adult (⩾ 18 yr) seen between October 2002 2003...
Background— Novel therapies have recently become available for pulmonary arterial hypertension. We conducted a study to characterize mortality in multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated hypertension the modern management era. Methods and Results— Between October 2002 2003, 354 consecutive adult (56 incident 298 prevalent cases) were prospectively enrolled. Patients followed up 3 years, survival rates analyzed. For cases,...
Severe pulmonary hypertension occurs occasionally in patients with chronic obstructive disease (COPD), but no detailed description of these is available.To identify and characterize COPD severe hypertension.Retrospective study 27 (pulmonary artery mean pressure [Ppa], > or = 40 mm Hg) among 998 who underwent right heart catheterization between 1990 2002 as part a workup for respiratory failure during period stability.Of the patients, 16 had another capable causing hypertension. The remaining...
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674 consecutive adult patients who were prospectively enrolled in the French PAH registry (121 incident and 553 prevalent cases). Two survival analyses performed. First, cohort of was followed for 3 yrs after study entry rates described. Then, we focused on subset with idiopathic, familial anorexigen-associated (n = 56) combined diagnosed <3 prior to 134). In patients, 1-, 2-, 3-yr 87% (95% CI 84–90), 76%...
Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between number low-risk criteria achieved within 1 year diagnosis and long-term prognosis. Incident idiopathic, heritable drug-induced PAH 2006 2016 were analysed. present at first re-evaluation assessed: World Health Organization (WHO)/New York Heart Association (NYHA) functional class I or II, 6-min walking distance...
The association of chronic obstructive pulmonary disease (COPD) and sleep apnea syndrome (SAS), which are both frequent diseases, is likely to occur in a number patients. We have prospectively investigated large series (n = 265) patients who were selected solely on the basis confirmed diagnosis SAS (apnea + hypopnea index > 20/hr). An spirographic pattern, defined by an FEV1/VC ratio < or 60%, was observed 30 265 (11%). These (subgroup "overlap") older (58 +/- 9) versus 53 10 yr, p 0.01)...
Telomere length is considered a marker for biological aging. Chronic obstructive pulmonary disease (COPD) may be associated with premature aging.To test the hypothesis that patients COPD experience accelerated telomere shortening and inflammation linked to this process.We measured length, using quantitative polymerase chain reaction-based method, plasma levels of various cytokines in 136 COPD, 113 age- sex-matched smokers, 42 nonsmokers normal lung function.Median (range) ratio was...
There is growing recognition of the clinical importance pulmonary haemodynamics during exercise, but several questions remain to be elucidated. The goal this statement assess scientific evidence in field order provide a basis for future recommendations.Right heart catheterisation gold standard method at rest and exercise. Exercise echocardiography cardiopulmonary exercise testing represent non-invasive tools with evolving applications. term "exercise hypertension" may most adequate describe...
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate long-term of patients with PAH categorized according to strategy. Methods: A retrospective analysis incident idiopathic, heritable, or anorexigen-induced enrolled French Pulmonary Hypertension Registry (January 2006 December 2018) was conducted. Survival assessed strategy: monotherapy, dual therapy, triple-combination therapy (two...
Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of achieve low status most remaining Our aim was to validate a four-stratum approach categorising intermediate-low, intermediate-high risk, proposed by the Comparative, Prospective Registry Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.We evaluated incident from French PAH and applied method at baseline first...
The prognostic value and the evolution of pulmonary hypertension (PH) in patients with markedly hypoxemic chronic obstructive disease (COPD), treated or not long-term oxygen therapy (LTOT), has been extensively investigated. However, little is known mildly moderately COPD requiring LTOT. Therefore, we assessed hemodynamics 131 stable by performing two right heart catheterizations at a mean (+/- SD) time interval 6.8 +/- 2.9 yr. At inclusion (T0), no patient had PH (i.e., artery pressure...
The beneficial effects of nocturnal oxygen therapy (NOT) in chronic obstructive pulmonary disease (COPD) patients with mild-to-moderate daytime hypoxaemia (arterial tension (Pa,O2) the range 7.4-9.2 kPa (56-69 mmHg)) and exhibiting sleep-related desaturation remains controversial. effectiveness NOT that category COPD was studied. end points included haemodynamic after 2 yrs follow-up, survival requirement for long-term (LTOT). Seventy-six could be randomized, 41 were allocated to 35 no...
Dexfenfluramine associated pulmonary arterial hypertension occurring in a patient with hereditary haemorrhagic telangiectasia related to mutation within the endoglin gene is described. This report highlights critical role of TGF-beta signalling pathway this condition.
The serotonin transporter (5-HTT) is involved in the pulmonary artery smooth muscle hyperplasia that leads to hypertension (PH). Because hypoxia and 5-HTT gene polymorphism control expression, we examined PH hypoxemic patients with advanced chronic obstructive disease (COPD).In 103 COPD recruited France (n=67) UK (n=36), determined pressure (PAP) measured during right heart catheterization (France) or Doppler echocardiography (UK). Ninety-eight subjects from 2 countries served as subjects....
Procoagulant microparticles constitute valuable hallmarks of cell damage. Microparticles also behave as cellular effectors.We hypothesized that the extent vascular damage measured by circulating could be related to severity pulmonary arterial hypertension (PAH).Circulating biomarkers and activation were in blood samples from 20 patients with PAH. Samples withdrawn occluded artery jugular vein. Peripheral venous obtained 23 control subjects. The microparticle procoagulant abilities quantified...